Versant Ventures

Portfolio Companies 2026 for Versant Ventures: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.

Versant Ventures accounts for 55 tracked companies with verified cap-table data, 55 of which disclose round sizes totalling $7B. The median disclosed raise is $100M, and the largest is Tubulis at $575M, ahead of RayzeBio ($418M) and Vividion Therapeutics ($362M).

The names that recur most often on these portfolio cap tables are Versant Ventures (55 companies), Casdin Capital (6 companies), Samsara BioCapital (5 companies), Alexandria Venture Investments (5 companies), RA Capital Management (5 companies), Logos Capital (5 companies). By latest disclosed round, the market skews Series A (29), Series B (10), Series C (7), Series D (3).

Best funded Versant Ventures companies

  1. Tubulis — $575M (latest: Series A)
  2. RayzeBio — $418M (latest: Series D)
  3. Vividion Therapeutics — $362M (latest: Series B)
  4. GenSight Biologics — $264M
  5. Boundless Bio — $256M (latest: Series C)
  6. Aerami Therapeutics — $250M (latest: IPO)
  7. Bright Peak Therapeutics — $232M (latest: Series C)
  8. Aligos Therapeutics — $225M (latest: Series B)
  9. Intuity Medical — $210M (latest: Series F)
  10. Black Diamond Therapeutics — $194M (latest: Series C)
  11. Santa Ana Bio — $168M (latest: Series B)
  12. Century Therapeutics — $160M (latest: Series C)
  13. Anokion — $160M (latest: Series B)
  14. Gritstone Oncology — $157M (latest: Series A)
  15. Borealis Biosciences — $150M (latest: Series A)

Versant Ventures VII GP-GP, LLC — related firms and companies (56)

Versant Ventures VII GP-GP, LLC profile · All research reports